Nay Nwe Nyein Chan
Associate Research ScientistCards
About
Research
Publications
2026
Temperature-Dependent Long-term and Short-term Stability of Human Epidermal Growth Factor 2 Antigenicity on Pathology Slides.
Scott L, Benanto J, Robbins C, Bates K, He M, Chan N, Rimm D. Temperature-Dependent Long-term and Short-term Stability of Human Epidermal Growth Factor 2 Antigenicity on Pathology Slides. Archives Of Pathology & Laboratory Medicine 2026 PMID: 41997586, DOI: 10.5858/arpa.2025-0447-oa.Peer-Reviewed Original ResearchPathological response to herceptin-containing neoadjuvant therapy in HER2 IHC2+/ISH+ and IHC3+ early-stage invasive ductal carcinoma
Jordan T, Chan N, Rimm D, Zhan H. Pathological response to herceptin-containing neoadjuvant therapy in HER2 IHC2+/ISH+ and IHC3+ early-stage invasive ductal carcinoma. Human Pathology 2026, 173: 106121. PMID: 41985721, DOI: 10.1016/j.humpath.2026.106121.Peer-Reviewed Original ResearchAdultAgedAntibodies, Monoclonal, HumanizedAntineoplastic Combined Chemotherapy ProtocolsBiomarkers, TumorBreast NeoplasmsCarcinoma, Ductal, BreastFemaleHumansImmunohistochemistryIn Situ Hybridization, FluorescenceMiddle AgedNeoadjuvant TherapyNeoplasm StagingNeoplasm, ResidualPathologic Complete ResponseRetrospective StudiesTrastuzumabTreatment OutcomeQuantitative HER2 tissue and plasma profiling predicts the activity of trastuzumab deruxtecan for breast cancer
Tarantino P, Kim S, Hughes M, Kusmick R, Smith K, Brasó-Maristany F, Nyein Chan N, Paré Brunet L, Alder L, Garcia-Cortes D, Gomez Tejeda Zanudo J, Pereslete A, Noteware L, Moore H, Van Swearingen A, Li T, Gupta H, D’Amico O, Martini A, Morganti S, Spindel J, Cook C, McLaughlin C, Dvir K, Garrido-Castro A, Sammons S, Files J, Sendrick K, Buck S, Dillon D, Jeselsohn R, Li Y, Cherniack A, LoRusso P, Lustberg M, Vega- León R, Pardo F, Davis J, Mueller C, Corgiat B, Curigliano G, Anders C, Petricoin E, Rimm D, Prat A, Tayob N, Lin N, Tolaney S. Quantitative HER2 tissue and plasma profiling predicts the activity of trastuzumab deruxtecan for breast cancer. Npj Precision Oncology 2026, 10: 141. PMID: 41826432, PMCID: PMC13046964, DOI: 10.1038/s41698-026-01365-6.Peer-Reviewed Original ResearchQuantitative Assays for TROP2 Measurement in Breast Cancer and Comparison to H-Score
He M, Chan N, Liu M, Robbins C, Bates K, Benanto J, Colón-Cartagena L, Kahila M, Zhan H, Krishnamurti U, Moutafi M, Yaghoobi V, Liebler D, Fulton R, Rimm D. Quantitative Assays for TROP2 Measurement in Breast Cancer and Comparison to H-Score. Applied Immunohistochemistry & Molecular Morphology 2026, 34: 143-154. PMID: 41709478, PMCID: PMC13143368, DOI: 10.1097/pai.0000000000001311.Peer-Reviewed Original ResearchMetabolic characterization of tumor-immune interactions by multiplexed immunofluorescence reveals spatial mechanisms of immunotherapy response in non-small cell lung carcinoma (NSCLC)
Monkman J, Kilgallon A, Lawler C, Tubelleza R, Aung T, Warrell J, Vathiotis I, Trontzas I, Gavrielatou N, Nyein Chan N, Czertok R, Bookstein S, O’Byrne K, Markovits E, Rimm D, Kulasinghe A. Metabolic characterization of tumor-immune interactions by multiplexed immunofluorescence reveals spatial mechanisms of immunotherapy response in non-small cell lung carcinoma (NSCLC). Nature Communications 2026, 17: 837. PMID: 41634004, PMCID: PMC12868679, DOI: 10.1038/s41467-026-68633-8.Peer-Reviewed Original Research
2025
Validation and Prospective Testing of a High-Sensitivity, Quantitative Analytic Assay for HER2 on Histopathology Slides
Chan N, Gaule P, Benanto J, Scott L, Robbins C, He M, Bates K, Khaimova R, Liebler D, Fulton R, Rimm D. Validation and Prospective Testing of a High-Sensitivity, Quantitative Analytic Assay for HER2 on Histopathology Slides. Laboratory Investigation 2025, 105: 104233. PMID: 40882816, PMCID: PMC12500179, DOI: 10.1016/j.labinv.2025.104233.Peer-Reviewed Original ResearchQuantitative assessment of HER2 expression in invasive ductal carcinoma and co-existing DCIS
Zhan H, Chan N, Khaimova R, Aung T, Gaule P, Robbins C, Rimm D. Quantitative assessment of HER2 expression in invasive ductal carcinoma and co-existing DCIS. Breast Cancer Research And Treatment 2025, 213: 273-279. PMID: 40679712, DOI: 10.1007/s10549-025-07781-9.Peer-Reviewed Original ResearchQuantitative Multiplex Immunofluorescence Assay for Trophoblast Cell-Surface Antigen 2 and Human Epidermal Growth Factor Receptor 2 Expression in Breast Cancer: Toward Guiding Patient Selection for Antibody-Drug Conjugate Therapies
Robbins C, He M, Chan N, Khaimova R, Bates K, Trontzas I, Scott L, Moutafi M, Coleman C, Hill S, Liebler D, Fulton R, Rimm D. Quantitative Multiplex Immunofluorescence Assay for Trophoblast Cell-Surface Antigen 2 and Human Epidermal Growth Factor Receptor 2 Expression in Breast Cancer: Toward Guiding Patient Selection for Antibody-Drug Conjugate Therapies. JCO Precision Oncology 2025, 9: e2500128. PMID: 40669019, PMCID: PMC12490811, DOI: 10.1200/po-25-00128.Peer-Reviewed Original ResearchThis study investigates a multiplex immunofluorescence assay for measuring HER2 and TROP2 in breast cancer, showing potential to guide personalized antibody-drug conjugate therapies.Pathologist-Read vs AI-Driven Assessment of Tumor-Infiltrating Lymphocytes in Melanoma
Aung T, Liu M, Su D, Shafi S, Boyaci C, Steen S, Tsiknakis N, Vidal J, Maher N, Micevic G, Tan S, Vesely M, Nourmohammadi S, Bai Y, Djureinovic D, Wong P, Bates K, Chan N, Gavirelatou N, He M, Burela S, Barna R, Bosic M, Bräutigam K, Illabochaca I, Chenhao Z, Gama J, Kreis B, Mohacsi R, Pillar N, Pinto J, Poulios C, Toli M, Tzoras E, Bracero Y, Bosisio F, Cserni G, Dema A, Fortarezza F, Gonzalez M, Gullo I, Gutiérrez F, Hacihasanoglu E, Jovic V, Lazar B, Olinca M, Neppl C, Oliveira R, Pezzuto F, Pinto D, Plotar V, Pop O, Rau T, Skok K, Sun W, Serbes E, Solass W, Stanowska O, Szasz M, Szymonski K, Thimm F, Vignati D, Vigdorovits A, Prieto V, Sinnberg T, Wilmott J, Cowper S, Warrell J, Saenger Y, Hartman J, Plummer J, Osman I, Rimm D, Acs B. Pathologist-Read vs AI-Driven Assessment of Tumor-Infiltrating Lymphocytes in Melanoma. JAMA Network Open 2025, 8: e2518906. PMID: 40608341, PMCID: PMC12232186, DOI: 10.1001/jamanetworkopen.2025.18906.Peer-Reviewed Original ResearchQuantitative Protein Expression of Antibody-Drug Conjugate Targets in EGFR Mutated and Wild-Type Non-Small Cell Lung Cancer
Trontzas I, He M, Wurtz A, Robbins C, Robinson N, Bates K, Liu M, Aung T, Scott L, Chan N, Burela S, Schillo J, Liebler D, Hill S, Morrison R, Vathiotis I, Syrigos K, Goldberg S, Politi K, Rimm D. Quantitative Protein Expression of Antibody-Drug Conjugate Targets in EGFR Mutated and Wild-Type Non-Small Cell Lung Cancer. Clinical Cancer Research 2025, 31: 2767-2776. PMID: 40047548, PMCID: PMC12213210, DOI: 10.1158/1078-0432.ccr-24-3347.Peer-Reviewed Original Research
News
News
Get In Touch
Contacts
Email
Mailing Address
Yale School of Medicine
Quantitative Diagnostics in Anatomic Pathology (QDAP) Laboratory , 15 York Street, LMP-B101
NEW HAVEN, CONNECTICUT 06510
United States
Locations
Quantitative Diagnostics in Anatomic Pathology (QDAP) Laboratory
Lab
Laboratory for Medicine and Pediatrics (LMP)
15 York Street, Fl B, Rm 101
New Haven, CT 06510